Buy Local, Buy Wisconsin Grants 2025

The FY24 BCRP Clinical Research Extension Award is a specialized grant mechanism designed to maximize the clinical impact of previously funded breast cancer clinical studies. The core purpose is to extend or expand the data collection, patient follow-up, and subsequent analysis of these existing trials. This is strategically aligned with the BCRP's mission to prevent the loss of invaluable knowledge that can occur due to early trial termination, limited patient follow-up, or suboptimal use of collected specimens and data. By supporting research that maximizes the value of patient contributions—such as tissue, serum, and data—the mechanism ensures that science respects and utilizes these contributions to accelerate progress toward ending breast cancer. The grant's impact goals are focused on extending or enhancing the influence of a previously funded clinical study, or generating completely new impact toward ending breast cancer. The ultimate beneficiaries include the American public, and specifically active-duty Service Members, Veterans, and military beneficiaries, as the proposed research must demonstrate relevance to these populations. The program strongly encourages collaborations between researchers at military/Veteran institutions and non-military institutions to leverage unique knowledge and access to clinical populations, thereby advancing cancer research critical to military families and the American public. The CDMRP also encourages applicants to review and address the recommendations of the congressionally mandated Metastatic Cancer Task Force. Key priorities and focus areas guide the research scope. Although not exhaustive, supported research may include deeper molecular analysis of existing clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients from open or completed trials. The proposed work can be hypothesis-testing or -generating, but it specifically prohibits the conduct of new clinical trials. The program also prioritizes collaboration through the Partnering PI Option, accommodating two Principal Investigators (PIs) who bring distinct, yet equally valued, intellectual contributions to the project. A non-negotiable priority is the inclusion of two or more breast cancer Consumer Advocates who must provide objective input on the study's design and execution, focusing on the research's potential impact for individuals with, or at risk for, breast cancer. Expected outcomes and measurable results are rooted in rigorous data evaluation and sharing. Applicants must propose a study sample size that guarantees the generation of valid conclusions or a meaningful hypothesis, along with sufficient evidence and statistical methods to support their objectives. A required outcome is the outline of a robust data-sharing plan, ensuring that the scientific community will have access to the experimental platforms, molecular data, and other information generated from the research. The program anticipates funding approximately two Clinical Research Extension Award applications with a total allotment of approximately $18.6 million. The maximum direct cost for the entire period of performance is $5 million for a single PI application and $6 million for the Partnering PI Option.